Cutaneous Lupus Erythematosus: Diagnostic and Therapeutic Recommendations of the Polish Dermatological Society

In 2018, the Polish Dermatological Society issued recommendations for the diagnosis and treatment of cutaneous lupus erythematosus (CLE), an autoimmune disease that can be isolated to the skin or part of systemic lupus erythematosus (SLE). They advised individualized treatment plans, which include lifestyle modifications, topical treatments, and systemic medications. For severe cases, antimalarials or systemic glucocorticosteroids were recommended, with methotrexate, retinoids, sulphones, and mycophenolate mofetil as second and third-line medications. The document also outlined the importance of histopathological examination and direct immunofluorescence for diagnosis, and it discussed drug-induced lupus erythematosus (DILE), its triggers, and prophylactic measures. Additionally, it highlighted the need for effective contraception during treatment and monitoring of anti-Ro antibodies in pregnant women. The recommendations emphasized the importance of monitoring the therapeutic process and suggested withdrawal of treatment for patients without organ manifestations a year after the resolution of skin lesions.